Nectar Lifesciences P/E Ratio
Nectar Lifesciences (NECLIFE) P/E ratio is not applicable — EPS (TTM) ₹-5.07, 3 consecutive loss quarters. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company has reported losses in the last 3 quarters. P/E ratio is not applicable during loss periods.
Consecutive Loss Quarters: 3
Current EPS: ₹-5.07
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Sept 2025 | -7.85 | -176 | Loss |
| Mar 2025 | -5.80 | -130 | Loss |
| Jun 2025 | -2.82 | -63 | Loss |
| Dec 2025 | 0.64 | 14 | Profit |
| Sept 2024 | 0.25 | 6 | Profit |
| Mar 2024 | 0.03 | 1 | Profit |
| Jun 2024 | 0.13 | 3 | Profit |
| Dec 2024 | 0.35 | 8 | Profit |
Healthcare Peers with Valid P/E Ratios — NECLIFE Comparison
Healthcare sector average P/E 53.66, median 27.43 — NECLIFE excluded (negative EPS).
Sector Average PE
53.66
Sector Median PE
27.43
Lowest PE
1.03
Profitable Companies
193
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Welcure Drugs & Pharmace… | WELCURE | 1.03 | ₹36 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 4.19 | ₹71 | Low |
| Ind Swift Laboratories | INDSWFTLAB | 4.7 | ₹1,105 | Low |
| Amwill Health Care | AMWILL | 6.71 | ₹71 | Low |
| Shelter Pharma | SHELTER | 6.75 | ₹49 | Low |
| Mono Pharmacare | MONOPHARMA | 7.44 | ₹23 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹68 | Low |
| Par Drugs & Chemical | PAR | 8.09 | ₹113 | Low |
| Galaxy Medicare | GML | 8.65 | ₹29 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see Nectar Lifesciences share price today.
- Check Nectar Lifesciences market worth to track the company's total market size over time.
- Compare with NECLIFE stock valuation models to assess whether the stock is under or overvalued.